Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
AstraZeneca
Covington
Teva
Cerilliant
Chubb
Healthtrust
Cantor Fitzgerald
Baxter
Colorcon

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,187,632

« Back to Dashboard

Which drugs does patent 8,187,632 protect, and when does it expire?

Patent 8,187,632 protects CIPRO XR and is included in one NDA.

Protection for CIPRO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 8,187,632
Title:Sustained-release preparations of quinolone antibiotics
Abstract: The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.
Inventor(s): Kanikanti; Venkata-Rangarao (Leverkusen, DE), Rupp; Roland (Bergisch Gladbach, DE), Weber; Wolfgang (Cologne, DE), Deuringer; Peter (Cologne, DE), Henck; Jan-Olav (Willich, DE), Stab; Heino (Cologne, DE), Nishioka; Takaaki (Nabari, JP), Katakawa; Yoshifumi (Kusatsu, JP), Taniguchi; Chika (Nishinomiya, JP), Ichihashi; Hitoshi (Suita, JP)
Assignee: Bayer Schering Pharma AG (Leverkusen, DE)
Application Number:11/762,831
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,187,632

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare CIPRO XR ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021473-001 Dec 13, 2002 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bayer Hlthcare CIPRO XR ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021473-002 Aug 28, 2003 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,187,632

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany100 31 043Jun 26, 2000

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Queensland Health
Fish and Richardson
Baxter
Chubb
Teva
Citi
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot